{"id":"NCT01662531","sponsor":"CSL Behring","briefTitle":"A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B","officialTitle":"A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-10","completion":null,"firstPosted":"2012-08-10","resultsPosted":"2016-05-09","lastUpdate":"2016-05-09"},"enrollment":27,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia B"],"interventions":[{"type":"BIOLOGICAL","name":"rIX-FP","otherNames":[]}],"arms":[{"label":"rIX-FP","type":"EXPERIMENTAL"}],"summary":"This study will examine the pharmacokinetics, safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children who have previously received factor replacement therapy for hemophilia B.","primaryOutcome":{"measure":"Incremental Recovery Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product","timeFrame":"30 minutes after infusion","effectByArm":[{"arm":"rIX-FP","deltaMin":1.0114,"sd":0.22711},{"arm":"Age < 6 Years","deltaMin":0.9506,"sd":0.20432},{"arm":"Age 6 to <12 Years","deltaMin":1.06,"sd":0.23934}],"pValues":[]},"eligibility":{"minAge":null,"sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":17,"countries":["Australia","Austria","Canada","Czechia","France","Germany","Israel","Italy","Russia","Spain"]},"refs":{"pmids":["37522479","27583313"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":27},"commonTop":["Pyrexia","Contusion","Cough","Nasopharyngitis","Arthralgia"]}}